Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 473-481

  Peng, Aaron ^a   Straubinger, Robert M ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

factor VIII; hemophilia A; immunogenicity; inhibitor development; phosphatidylinositol

Indexed keywords

BLOOD CLOTTING FACTOR 8; PHOSPHATIDYLINOSITOL; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPHILIA A; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN STABILITY; T LYMPHOCYTE; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ANIMALS; FACTOR VIII; FEMALE; HEMOPHILIA A; LIPIDS; MALE; MICE; PHOSPHATIDYLINOSITOLS;

EID: 77955962214     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9207-z     Document Type: Article

References (55)

1. PA Foster TS Zimmerman 1989 Factor VIII structure and function Blood Rev 3 3 180 191 10.1016/0268-960X(89)90015-5 2506958 1:STN:280: DyaK3c%2FgtFOjtA%3D%3D
2. PJ Fay 1993 Factor VIII structure and function Thromb Haemost 70 1 63 67 8236116 1:CAS:528:DyaK3sXltFWrsrw%3D
3. RJ Kaufman LC Wasley AJ Dorner 1988 Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells J Biol Chem 263 13 6352 6362 3129422 1:CAS:528:DyaL1cXktVWrsro%3D
4. PJ Lenting CJ VANS CV Denis 2007 Clearance mechanisms of von Willebrand factor and factor VIII J Thromb Haemost 5 7 1353 1360 10.1111/j.1538-7836.2007. 02572.x 17425686 1:CAS:528:DC%2BD2sXovVOnu7s%3D
5. EL Saenko NM Ananyeva 2006 Receptor-mediated clearance of factor VIII: implications for pharmacokinetic studies in individuals with haemophilia Haemophilia 12 15 22 10.1111/j.1365-2516.2006.01329.x 1:CAS:528: DC%2BD2sXitFylug%3D%3D
6. M Nishino JP Girma C Rothschild E Fressinaud D Meyer 1989 New variant of von Willebrand disease with defective binding to factor VIII Blood 74 5 1591 1599 2506947 1:CAS:528:DyaK3cXlsFKk
7. M Morfini PM Mannucci PM Tenconi G Longo MG Mazzucconi F Rodeghiero, et al. 1993 Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease Thromb Haemost 70 2 270 272 8236134 1:STN:280:DyaK2c%2FlsVeisA%3D%3D
8. EG Tuddenham RS Lane F Rotblat AJ Johnson TJ Snape S Middleton, et al. 1982 Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease Br J Haematol 52 2 259 267 10.1111/j.1365-2141.1982.tb03888.x 6812613 1:STN:280: DyaL3s%2Fit12gsQ%3D%3D
9. EL Saenko D Scandella 1997 The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor J Biol Chem 272 29 18007 18014 10.1074/jbc.272.29.18007 9218428 1:CAS:528:DyaK2sXkslKntL8%3D
10. RJ Hamer JA Koedam NH Beeser-Visser RM Bertina JA Van Mourik JJ Sixma 1987 Factor VIII binds to von Willebrand factor via its Mr-80, 000 light chain Eur J Biochem 166 1 37 43 10.1111/j.1432-1033.1987.tb13480.x 3109914 1:CAS:528:DyaL2sXksFKmsbw%3D
11. P Lollar DC Hill-Eubanks CG Parker 1988 Association of the factor VIII light chain with von Willebrand factor J Biol Chem 263 21 10451 10455 3134349 1:CAS:528:DyaL1cXkslWjtrg%3D
12. A Leyte MP Verbeet T Brodniewicz-Proba JA Van Mourik K Mertens 1989 The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII Biochem J 257 3 679 683 2494987 1:CAS:528:DyaL1MXpt1Kksw%3D%3D
13. EL Saenko M Shima KJ Rajalakshmi D Scandella 1994 A role for the C2 domain of factor VIII in binding to von Willebrand factor J Biol Chem 269 15 11601 11605 7512568 1:CAS:528:DyaK2cXivFCqtb4%3D
14. EL Saenko AV Yakhyaev I Mikhailenko DK Strickland AG Sarafanov 1999 Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism J Biol Chem 274 53 37685 37692 10.1074/jbc.274.53.37685 10608826 1:CAS:528:DC%2BD3cXkt1Ghtg%3D%3D
15. PJ Lenting JG Neels BM van den Berg PP Clijsters DW Meijerman H Pannekoek, et al. 1999 The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein J Biol Chem 274 34 23734 23739 10.1074/jbc.274.34.23734 10446132 1:CAS:528:DyaK1MXlsVOns7c%3D
16. EL Saenko D Scandella AV Yakhyaev NJ Greco 1998 Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets J Biol Chem 273 43 27918 27926 10.1074/jbc.273.43.27918 9774404 1:CAS:528:DyaK1cXntVCmtLo%3D
17. GE Gilbert D Drinkwater 1993 Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine Biochemistry 32 37 9577 9585 10.1021/bi00088a009 8373765 1:CAS:528:DyaK3sXlsFKqsrg%3D
18. GE Gilbert RJ Kaufman AA Arena H Miao SW Pipe 2002 Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs J Biol Chem 277 8 6374 6381 10.1074/jbc.M104732200 11698391 1:CAS:528:DC%2BD38XhvFyqsr0%3D
19. KP Pratt BW Shen K Takeshima EW Davie K Fujikawa BL Stoddard 1999 Structure of the C2 domain of human factor VIII at 1.5 A resolution Nature 402 6760 439 442 10.1038/46601 10586887 1:CAS:528:DyaK1MXnvFSisrs%3D
20. EL Saenko D Scandella 1995 A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor J Biol Chem 270 23 13826 13833 10.1074/jbc.270.23.13826 7775440 1:CAS:528:DyaK2MXmt1yqsLo%3D
21. G Kemball-Cook TW Barrowcliffe 1992 Interaction of factor VIII with phospholipids: role of composition and negative charge Thromb Res 67 1 57 71 10.1016/0049-3848(92)90258-C 1440515 1:CAS:528:DyaK38XlsVOqsbo%3D
22. MG Jacquemin JM Saint-Remy 1998 Factor VIII immunogenicity Haemophilia 4 4 552 557 10.1046/j.1365-2516.1998.440552.x 9873793 1:STN:280: DyaK1M%2FptVCkuw%3D%3D
23. P Lollar JF Healey RT Barrow ET Parker 2001 Factor VIII inhibitors Adv Exp Med Biol 489 65 73 11554592 1:CAS:528:DC%2BD38XislOmtbo%3D
24. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2003 Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII J Thromb Haemost 1 8 1777 1784 10.1046/j.1538-7836.2003.00251.x 12911593 1:CAS:528:DC%2BD2cXktFGktbs%3D
25. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2004 Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII J Thromb Haemost 2 8 1385 1394 10.1111/j.1538-7836.2004.00850.x 15304045 1:CAS:528:DC%2BD2cXns1ais7k%3D
26. GL Hu DK Okita BM Conti-Fine 2004 T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects J Thromb Haemost 2 11 1908 1917 10.1111/j.1538-7836.2004.00918.x 15550021 1:CAS:528:DC%2BD2cXhtFagsLzI
27. VS Purohit K Ramani R Sarkar HH Kazazian Jr SV Balasubramanian 2005 Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex J Biol Chem 280 18 17593 17600 10.1074/jbc.M500163200 15728582 1:CAS:528:DC%2BD2MXjsl2itLk%3D
28. K Ramani RD Miclea VS Purohit DE Mager RM Straubinger SV Balu-Iyer 2008 Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A J Pharm Sci 97 4 1386 1398 10.1002/jps.21102 17705286 1:CAS:528:DC%2BD1cXkt1CgsLk%3D
29. JA Kamps HW Morselt GL Scherphof 1999 Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo-in vitro differences Biochem Biophys Res Commun 256 1 57 62 10.1006/bbrc.1999.0290 10066422 1:CAS:528:DyaK1MXhsVCkt74%3D
30. JA Kamps GL Scherphof 1998 Receptor versus non-receptor mediated clearance of liposomes Adv Drug Deliv Rev 32 1-2 81 97 10837637
31. A Gabizon D Papahadjopoulos 1988 Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc Natl Acad Sci USA 85 18 6949 6953 10.1073/pnas.85.18.6949 3413128 1:CAS:528:DyaL1cXlslKhtLc%3D
32. GR Bartlett 1959 Phosphorus assay in column chromatography J Biol Chem 234 3 466 468 13641241 1:CAS:528:DyaG1MXmtlWjtg%3D%3D
33. TD Heath BA Macher D Papahadjopoulos 1981 Covalent attachment of immunoglobulins to liposomes via glycosphingolipids Biochim Biophys Acta 640 1 66 81 10.1016/0005-2736(81)90532-0 6163457 1:CAS:528:DyaL3MXotFyksw%3D%3D
34. VS Purohit CR Middaugh SV Balasubramanian 2006 Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice J Pharm Sci 95 2 358 371 10.1002/jps.20529 16372314 1:CAS:528:DC%2BD28XhsFeks70%3D
35. L Bi AM Lawler SE Antonarakis KA High JD Gearhart HH Kazazian Jr 1995 Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat Genet 10 1 119 121 10.1038/ng0595-119 7647782 1:CAS:528:DyaK2MXlsVymt7o%3D
36. J Qian M Borovok L Bi HH Kazazian Jr LW Hoyer 1999 Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A Thromb Haemost 81 2 240 244 10063999 1:CAS:528:DyaK1MXhvVGrtbw%3D
37. C Denis N Methia PS Frenette H Rayburn M Ullman-Cullere RO Hynes, et al. 1998 A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis Proc Natl Acad Sci USA 95 16 9524 9529 10.1073/pnas.95.16.9524 9689113 1:CAS:528:DyaK1cXltlClsL0%3D
38. R Sarkar W Xiao HH Kazazian Jr 2003 A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype J Thromb Haemost 1 2 220 226 10.1046/j.1538-7836.2003.00096.x 12871492 1:CAS:528:DC%2BD2cXktFenu7o%3D
39. E Berntorp S Bjorkman 2003 The pharmacokinetics of clotting factor therapy Haemophilia 9 4 353 359 10.1046/j.1365-2516.2003.00762.x 12828668 1:CAS:528:DC%2BD3sXmsFGisLk%3D
40. A Messori G Longo M Matucci M Morfini PL Ferrini 1987 Clinical pharmacokinetics of factor VIII in patients with classic haemophilia Clin Pharmacokinet 13 6 365 380 10.2165/00003088-198713060-00002 3125001 1:STN:280:DyaL1c7js1eqsQ%3D%3D
41. B Verbruggen I Novakova H Wessels J Boezeman M van den Berg E Mauser-Bunschoten 1995 The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability Thromb Haemost 73 2 247 251 7792738 1:CAS:528:DyaK2MXjsl2hs70%3D
42. K Ramani V Purohit CR Middaugh SV Balasubramanian 2005 Aggregation kinetics of recombinant human FVIII (rFVIII) J Pharm Sci 94 9 2023 2029 10.1002/jps.20432 16052549 1:CAS:528:DC%2BD2MXpslOgtLs%3D
43. K Ramani VS Purohit RD Miclea CR Middaugh SV Balasubramanian 2005 Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII) J Pharm Sci 94 6 1288 1299 10.1002/jps.20340 15858858 1:CAS:528:DC%2BD2MXkvF2qtLk%3D
44. BD Griffin LR Micklem MC McCann K James DS Pepper 1986 The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII Thromb Haemost 55 1 40 46 3085263 1:CAS:528: DyaL28XhsVKrsrs%3D
45. SJ Comiskey TD Heath 1990 Serum-induced leakage of negatively charged liposomes at nanomolar lipid concentrations Biochemistry 29 15 3626 3631 10.1021/bi00467a006 2340262 1:CAS:528:DyaK3cXhs1CrtLg%3D
46. M Grit DJ Crommelin 1993 Chemical stability of liposomes: implications for their physical stability Chem Phys Lipids 64 1-3 3 18 10.1016/0009-3084(93) 90053-6 8242840 1:CAS:528:DyaK3sXmslyntrs%3D
47. A Braun L Kwee MA Labow J Alsenz 1997 Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice Pharm Res 14 10 1472 1478 10.1023/A:1012193326789 9358564 1:CAS:528:DyaK2sXntFehtL0%3D
48. AJ Chirino ML Ary SA Marshall 2004 Minimizing the immunogenicity of protein therapeutics Drug Discov Today 9 2 82 90 10.1016/S1359-6446(03)02953-2 15012932 1:CAS:528:DC%2BD2cXhvFWitLw%3D
49. B Elder D Lakich J Gitschier 1993 Sequence of the murine factor VIII cDNA Genomics 16 2 374 379 10.1006/geno.1993.1200 8314577 1:CAS:528: DyaK3sXmtFyksbk%3D
50. S Stoilova-McPhie BO Villoutreix K Mertens G Kemball-Cook A Holzenburg 2002 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography Blood 99 4 1215 1223 10.1182/blood.V99.4.1215 11830468 1:CAS:528:DC%2BD38XhtlWqsLY%3D
51. AO Grillo KL Edwards RS Kashi KM Shipley L Hu MJ Besman, et al. 2001 Conformational origin of the aggregation of recombinant human factor VIII Biochemistry 40 2 586 595 10.1021/bi001547t 11148054 1:CAS:528: DC%2BD3cXovV2ktrs%3D
52. VS Purohit K Ramani RS Kashi MJ Durrani TJ Kreiger SV Balasubramanian 2003 Topology of factor VIII bound to phosphatidylserine-containing model membranes Biochim Biophys Acta 1617 1-2 31 38 14637017 1:CAS:528: DC%2BD3sXptVShsb0%3D
53. AJ Vlot SJ Koppelman MH van den Berg BN Bouma JJ Sixma 1995 The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor Blood 85 11 3150 3157 7756647 1:CAS:528:DyaK2MXlvFehurY%3D
54. NM Wassef F Roerdink EC Richardson CR Alving 1984 Suppression of phagocytic function and phospholipid metabolism in macrophages by phosphatidylinositol liposomes Proc Natl Acad Sci USA 81 9 2655 2659 10.1073/pnas.81.9.2655 6326135 1:CAS:528:DyaL2cXkt1Wru7k%3D
55. E Caselli OR Baricordi L Melchiorri F Bellini D Ponzin A Bruni 1992 Inhibition of DNA synthesis in peripheral blood mononuclear cells treated with phosphatidylserines containing unsaturated acyl chains Immunopharmacology 23 3 205 213 10.1016/0162-3109(92)90027-A 1500286 1:CAS:528:DyaK38Xks1aqtb8%3D